According to Cleveland Clinic, venous thromboembolism (VTE) is a disease that includes both deep vein thrombosis (DVT) and pulmonary embolism (PE). It is a common, lethal disorder that affects hospitalized and non-hospitalized patients, recurs frequently, is often overlooked, and results in long-term complications, including chronic thromboembolic pulmonary hypertension (CTPH) and post-thrombotic syndrome (PTS). An inclusive scientific review by the WTD steering committee revealed that 10 million cases of VTE occur annually – across low, middle, and high-income countries. In addition, up to 60% of VTE cases occur during or after hospitalization, making it a leading preventable cause of hospital death. The venous thromboembolism treatment market can be segmented into diseases such as deep venous thrombosis (DVT) and pulmonary embolism (PE). The venous thromboembolism treatment market is segmented based on drugs such as heparin, apixaban, dabigatran, rivaroxaban, edoxaban, and warfarin. The therapy market for VTE treatment comprises compression therapy and thrombolytic therapy.
The key drivers assisting the overall market growth of venous thromboembolism treatment are increasing prevalence and incidence rate of venous thromboembolism, and high awareness related to existing treatments for venous thromboembolism are driving the global venous thromboembolism treatment market. In addition, factors such as stringent regulatory approvals and challenges in adapting newer drugs and therapies in the market are restraining the growth of this market. North America is the leading regional market for venous thromboembolism treatments. Europe trails it due to a large population suffering from venous thromboembolic in these regions. The key factors driving North America and Europe’s venous thromboembolism market are high healthcare expenditure, developed healthcare infrastructure, and high awareness of the disease and available treatments.
The global venous thromboembolism treatment market is segmented on the following bases:
Type of Disease
Deep Venous Thrombosis
Pulmonary Embolism
Type of Treatment
Therapeutics
Heparin
Apixaban
Dabigatran
Rivaroxaban
Edoxaban
Warfarin
Other Treatments
Compression Therapy
Inferior Vena Cava Filter
Thrombolytic Therapy
Geography
North America
US
Canada
Europe
UK
Germany
Rest of Europe
Asia-Pacific
Japan
China
Rest of APAC
Latin America
Middle East and Africa
Key Players Identified for Venous Thromboembolism Treatment Market Include but are Not Limited to:
Abbott Laboratories, Merck & Co., Sanofi S.A., Dupont Pharm Co, Boehringer Ingelheim GmbH, Upsher-Smith Laboratories, Inc., Wockhardt Ltd, Bayer AG, Bristol-Myers Squibb Company, 3M Health Care, ArjoHuntleigh, BSN medical, Medtronic plc, Bio Compression Systems, Inc., and Pfizer Inc. and others.
This report offers:
An overview of the global markets for venous thromboembolism treatment
Market trends assessment for the period 2014-2022, with historical information for 2014 & 2015 and projections through 2022, with respective CAGRS during 2016-2022
Qualitative assessment tools such as market drivers, challenges, and opportunities
Market competition scrutiny tools such as market share analysis, fractal map assessment, Porter’s Five Forces model
Focus on each level of market segmentation based on product approvals, launches, and current and anticipated market dynamics.
A general overview of the industry structure
Company profiles highlighting key information about the major players operating in the venous thromboembolism treatment market
Frequently Asked Questions:
The market for Venous Thromboembolism (VTE) Treatment is expected to reach US$ XX Bn in 2022.
The Venous Thromboembolism (VTE) Treatment Market is expected to see significant CAGR growth over the coming years, at XX %.
